Novartis’ Lucentis Approved In Japan For Choroidal Neovascularization And Macular Edema
This article was originally published in PharmAsia News
Executive Summary
MHLW approved additional indications of choroidal neovascularization in pathological myopia and macular edema associated with retinal vein occlusion for Novartis Japan’s Lucentis intravitreal injection (ranibizumab).